# Proposed Framework to Evaluate the Quality and Reliability of Targeted Metabolomics Assays – a position statement and working proposal from the UK Consortium on Metabolic Phenotyping (MAP/UK)

Sarir Sarmad1, Mark Viant2, Warwick Dunn3,4, Royston Goodacre3, Ian Wilson5, Katie Chapell6, Jules Griffin7, Valerie O’Donnell8, Brendon Naicker8, Matthew Lewis6, Toru Suzuki1,9; on behalf of the UK Consortium on Metabolic Phenotyping (MAP/UK)

*1 Department of Cardiovascular Sciences, University of Leicester and NIHR Leicester Biomedical Research Centre, Leicester, UK.*

*2 Phenome Centre Birmingham, University of Birmingham, Birmingham, UK*

*3 Department of Biochemistry and Systems Biology, Institute of Systems, Molecular, and Integrative Biology, University of Liverpool, UK.*

*4 Institute of Metabolism and Systems Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom.*

*5 Computational & Systems Medicine, Department of Metabolism, Digestion and Reproduction, Imperial College, London, UK.*

*6 The National Phenome Centre, Imperial College, London, UK.*

*7 School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Aberdeen, UK.*

*8 Systems Immunity Research Institute, School of Medicine, Cardiff University, Cardiff, UK.*

*9 The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.*

# \* Address for Correspondence:

Prof Toru Suzuki

University of Leicester and NIHR Leicester Cardiovascular Biomedical Research Centre Glenfield Hospital, Leicester, LE3 9QP, UK

Email: ts263@le.ac.uk Tel: (0044) 116 204 4741

# Abstract

Targeted metabolite assays that measure tens or hundreds of pre-selected metabolites, typically using liquid chromatography mass spectrometry (LC-MS), are increasingly being developed and applied to metabolic phenotyping studies. These are used both as standalone phenotyping methods and for the validation of putative metabolic biomarkers obtained from untargeted metabolomics studies. However, there are no widely accepted standards in the scientific community for ensuring reliability of the development and validation of targeted metabolite assays (i.e. what we refer to here as targeted metabolomics). Most current practice attempts to adopt, with modification, the strict guidance provided by drug regulatory authorities for analytical methods designed largely for measuring drugs and other xenobiotic analytes.

Here, the regulatory guidance provided by the European Medicines Agency, U.S. Food and Drug Administration, and International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use are summarised. A less onerous ‘tiered’ approach to evaluate the reliability of a wide range of metabolomics analyses is proposed, addressing the need for community-accepted, harmonised guidelines for tiers other than full validation. This ‘fit-for-purpose’ tiered approach comprises 4 levels – discovery, screening, qualification and validation – and is discussed in the context of a range of targeted and untargeted metabolomics assays. Issues arising with targeted multiplexed metabolomics assays, and how these might be addressed, are considered. Furthermore, guidance is provided to assist the community with selecting the appropriate tier of reliability for a series of well- defined applications of metabolomics.

**Keywords:** Metabolic phenotyping, metabolomics, LC-MS, multiplexed assays, validation, qualification, screening, discovery, regulatory, tiered framework.

# Introduction

Metabolomics – or metabolic phenotyping - is a multidisciplinary field of research that investigates the metabolome, the terminal downstream products of the genome consisting of a repertoire of low molecular weight biomolecules involved in cellular metabolism and other biochemical processes (i.e. metabolites) in cells, tissues and bodily fluids 1,2. Metabolomics facilitates the characterization of a system from genomic to metabol(om)ic activity and its interaction with its environment, and reveals dynamic insight into multiple metabolic pathways and networks that are the consequences of cellular activity, to understand molecular pathophysiology 3. In addition, metabolomics aims to identify biomolecules (metabolite biomarkers) that modulate phenotype in physiological and/or disease status, reflective of biological processes as well as dysregulated pathways 4,5,6. The analytical approaches applied in metabolomics research are generally categorised as either untargeted, targeted, or a hybrid approach (otherwise defined as semi-targeted approach) that combines some aspects of both types of analyses 7.

The techniques that are most widely used for untargeted analysis include liquid chromatography high-resolution mass spectrometry (LC-MS), gas chromatography mass spectrometry (GC-MS) and 1H nuclear magnetic resonance (NMR) spectroscopy, while liquid chromatography-triple quad-tandem mass spectrometry (LC-MS/MS) remains one of the traditional techniques for targeted analysis of limited numbers of analytes, the other being GC-MS due to the fragmentation of the metabolite during electron ionisation 8,9. Untargeted metabolomics is a discovery-based approach where the objective is to analyse as many detectable metabolites without biological bias, including unknowns, to determine which, if any, are significantly perturbed in the diseased phenotype, followed by post-hoc identification of those putative metabolic biomarkers 10.The major disadvantage of untargeted approaches is that relative responses and not actual concentrations are reported. Targeted approaches on the other hand, involve the (multiplexed) analysis of known metabolites, and such methods often focus on a subset of metabolites representative of key pathways, or of metabolites determined to be important from prior untargeted metabolomics 11. The major disadvantage of targeted approaches is their limited coverage of the metabolome 12.

Advances in metabolomics have led to new clinical and toxicological diagnostic biomarkers 13, 14, 15, which can contribute to stratified medicine and safety assessment of drugs 16, 17. Metabolomics is also central to the screening of inborn errors of metabolism 18.

However, there are several challenges in the translation of metabolomics research to clinical and toxicological applications under regulatory control. Issues include analytical reproducibility, accuracy, precision, metabolite identification/quantification, study design, sample handling, lack of harmonised reporting frameworks for published data and metadata, insufficient open-access data to enable data-mining by other researchers 19, lack of harmonisation in bio-banking, batch-to-batch variation, and between-methods bias 20. Assessing the reliability of bioanalytical methods for metabolomics is challenging when compared to validation of other types of bioanalytical methods. Data from the metabolomics field are variable, and heterogeneity among data formats, data analysis pipelines, algorithms and applied statistical methods should be addressed. There is a need to define the scope and extent of assessing the reliability of these methods, and how the standards applied and methods for reporting should be set in order to ensure appropriate data quality for use in regulatory processes 21. To eliminate some of these problems, communication between the research and regulated clinical and toxicological communities needs to be more fully developed, and the establishment of a system to assess and cross-correlate metabolic profiles obtained by different laboratories and instruments is needed 19. The new Metabolomics Reporting Framework for regulatory toxicology, developed by multiple stakeholders from research laboratories, industry and government regulatory agencies and coordinated by the Organisation for Economic Co-operation and Development (OECD) provides evidence on how progress can be made to achieve harmonised reporting of methods, data, metadata and findings, and thereby advance the application of metabolomics within regulatory settings 22. There are also a plethora of publications that provide comprehensive guidelines for assessing the quality of untargeted metabolomics assays 23, 24, 25, 26, 27. Whilst these guidelines provide the foundation for metabolomics system suitability and quality assurance/quality control (QA/QC) proficiency, a community-initiated approach towards harmonised guidelines that ultimately achieve acceptance via their consensus use for evaluating the reliability of targeted metabolomics within research, clinical and toxicological settings is still required.

Our scientific collaboration, the UK Consortium on Metabolic Phenotyping (MAP/UK, https://mapuk.org), is a partnership of eight specialised research laboratories and two Phenome Centres, which has been funded by the Medical Research Council to improve UK-wide metabolic phenotyping expertise and capabilities. The MAP/UK partnership brings together a critical mass of methodological, analytical, and computational platforms to develop, optimise, transfer, harmonise, and validate efficient, high-quality metabolomics research and training methods, specifically tailored to the growing need for biomedical studies that require robust metabolic phenotyping. The overall aim of the MAP/UK partnership is to investigate new biomarkers within metabolic signatures of disease, novel targeted quantitative metabolomic and hybrid approaches, and developing untargeted metabolomics to meet gaps in molecular coverage of key disease-related pathways, alongside a variety of other factors, including dietary, lifestyle/environmental, gut microbial and genetics. As a collective of scientists with the aim of harmonisation of metabolic phenotyping, existing regulatory guidelines have been reviewed to extract commonalities from these guidelines that can be adopted to ‘fit-for- purpose’ and tiered approaches for untargeted and targeted metabolomics.

The aim of this manuscript is to propose harmonised guidelines for evaluating the reliability of targeted (multiplexed) mass spectrometry-based metabolomics assays taking into consideration intra-laboratory precision, accuracy, reproducibility, and cross-laboratory harmonisation of methods and data acquired on different instrumental platforms. First, existing guidelines for bioanalytical method validation, including an existing 4-tiered framework applied in drug discovery, are reviewed. Then, after introducing the applications of clinical and toxicological metabolomics in regulatory settings, a new ‘fit-for-purpose’ 4-tiered (discovery, screening, qualification and validation) framework for assessing analytical reliability that is suitable for targeted and hybrid untargeted metabolomics assays is proposed.

In addition, a checklist on the bioanalytical process has been provided to facilitate better understanding and emphasising the importance of harmonisation at each step.

**Checklist for bioanalytical assay process:**

1. **Pre-analytical:**
* Hypothesis/study design/ sample size
* Data acquisition of demographics for groups/individuals including clinical, diet, medications and life-style data
* Sample type (plasma/serum/urine/feces), collection method, preservation, and timing
* Sample storage
1. **Analytical:**
* Sample preparation and purification
* Authentic reference materials (external standards), quality control (QC) samples and suitable internal standards
* Maintaining assay reliability and quality by selecting the right tier based on number of metabolites and assay purpose (consult Table I).
* Select validation parameters and acceptance criteria for targeted assays (tier 1 and 2), by consulting Table II. Note that Tier 1 parameters are the same as suggested by regulatory guidelines (FDA/EMA/ICH2019) for validation, and Tier 2 (qualification) has a wider range of acceptance criteria.
* Select appropriate instrumentation such as liquid chromatography high-resolution mass spectrometry (LC-MS), liquid chromatography-triple quad-tandem mass spectrometry (LC-MS/MS), and considerations regarding instrument calibration, settings, analytical batches, and quality assurance (QA)/performance.

# The concept of regulatory bioanalytical validation

Validation is defined as a process that provides proof of assay integrity within given specifications with the parameters of an assay used for quantification being statistically reliable between assays over time. Multiple guidelines exist that describe the regulation of bioanalytical assays such as those from the U.S. Food and Drug Administration (FDA) 28, the European Medicines Agency (EMA) 29, the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) 30, Japanese Ministry of Health, Labour and Welfare (MHLW) 31, Chinese (State) Food and Drug Administration (CFDA, currently the National Medical Products Administration, NMPA) 32, Australian Therapeutic Goods Administration (TGA) 33, and Brazilian National Health Surveillance Agency (Anvisa) 34, 35, 36. The regional differences along with differences in terminology, parameters and acceptance criteria can cause confusion amongst bioanalysts and/or pharmaceutical companies given the globalisation of the pharmaceutical sector.

Whilst these regulatory guidelines are comprehensive, they are largely developed for the measurement of drugs and other xenobiotic analytes. Endogenous biomarkers are often measured in metabolomics which requires different considerations of matrix use. For example, with endogenous metabolites, the issue of evaluation of (L) LOQ (lower limit of quantification) encountered due to matrix effect. Evaluating these limits using standard solutions in neat solvent, and/or matrix deprived of specific classes of metabolites (such as stripped plasma) are not an ideal solution as what has been depleted is not defined. Furthermore, measurement of specificity/selectivity for endogenous metabolites is much more challenging due to presence of multiple isoforms.

The two most practised bioanalytical guidelines from the EMA and FDA are similar but not identical. The scientific basis for the evaluation of parameters is the same across both guidelines. However, there are also differences in terminology, recommended validation parameters, acceptance criteria and methodology.

Standards setting and harmonisation was advanced by the ICH, which is an international organisation with the mission to achieve greater harmonisation worldwide to ensure that safe, effective, and high-quality medicines are developed and registered in the most resource-efficient manner. The ICH consolidated best practices from the FDA and EMA guidelines in 2019 into a harmonised M10 bioanalytical method validation draft in order to clarify any areas of uncertainty between the two guidelines. A comparison between the FDA and EMA guidelines and the consolidated ICH M10 draft guideline are summarised in Table 1a (to be deposited on Figshare as supplemental material to this paper).

An analytical assay starts with a definition of its purpose (i.e. intended application), and to define what is ‘fit-for-purpose’ and is then followed by method development and optimisation, then subsequently by assay validation (dependent upon the tier, as introduced above) and documentation before it can finally be applied for the intended purpose. Prior to initiating a validation study, a well-planned validation protocol should be written and reviewed for scientific soundness and completeness. The protocol should describe the procedure in detail and should include pre-defined acceptance criteria and pre-defined statistical methods, and should be approved by all participants in the analytical pipeline.

There are numerous validation parameters (accuracy, precision, calibration curve, lower limit of quantitation, selectivity/specificity, carryover, analyte stability, recovery, dilution integrity, system suitability test, matrix effect/factor, parallelism, incurred sample re- analysis, quality control, robustness/ruggedness, hook/prozone effect, and minimum required dilution) to incorporate into the validation process. One should justify the required level of validation to be ‘fit-for-purpose’ based on the differing applications of a particular method. Theoretically, there are no limits to the extent of validation and verification procedures. However, in practice, there are both time and economic constraints on what can be achieved. Therefore, it is crucial to have optimised guidelines that are generally accepted, harmonised and cost-effective 47. The validation workflow has been summarized in a visual format (Fig. 1).



Figure 1- Validation workflow steps and positioning of the suggested framework (Table I and Table II) to select the most appropriate tier and degree of validation.

Before introducing our proposed framework to assist bioanalyst in selecting appropriate tier of validation for a series of well-defined applications of metabolomics, we give a brief introduction to the tiered approach within regulatory perspective in the next section.

**Tiered approach within regulatory perspectives**

The concept of defensible scientific flexibility has been a debate within the bioanalytical community in the pharmaceutical industry. The Crystal City III workshop proposed the concept of ‘fit-to-purpose’ in 2006 as an alternative for the full validation workflow already described by the FDA regulatory documents to address uncertainties in the bioanalytical community on what level of data scrutiny is required to generate quality data whilst optimising resources to meet study objectives with adequate level of data quality and reliability 37. Furthermore, the European Bioanalysis Forum (EBF) proposed the consolidation of tiered approaches to include three levels (or tiers) of quality standards for metabolite quantification for screening, qualified, and validated assays 38. Consequently, the MHLW and FDA adapted ‘flexible adjustments and modifications’ of their bioanalytical method validation guidelines to meet the intended use of the assay, and this perspective was extended to tiered approaches for metabolite quantification 39, 40, 41.

The Crystal City workshop VI in 2015 42 defined a less rigorous level of validation than the FDA guidelines for drug metabolite quantification at early stages of development. The Global Bioanalytical Consortium (GBC) assigned Team A2 with the objective of providing a framework to rationalise the level of bioanalytical methods for drug characterization and proposed a clear path for implementation and use of tiered approaches 39. Furthermore, two globally recognised teams within the GBC (S1 and L1) provided acceptance standards for validation methods for small and large pharmaceutical molecules, respectively 43. However, different terminologies have been used as part of the ‘fit-to-purpose’ concept, such as tiered assays, scientific validation, qualified assays or partial validation. Thus, it has been a source of confusion for academia and the biotechnology/pharmaceutical industry due to lack of clear guidance 39. More recently, these alternative validation assay workflows in the bioanalytical industry have been categorised into four tiered levels of method performance and evaluation based on the final purpose of the derived analytical data ranging from the most to least stringent: level 1) validation, intended for regulatory studies; 2) qualification; 3) research; and 4) the least stringent defined as ‘screening’39, 44, 45. These four tiered levels are described in more detail below, and whilst these concepts have been designed for drug development and submission to regulatory authorities, they provide a framework that could be adapted for a range of assays used in metabolomics studies.

* Level 1) **validated bioanalytical** **assays** are designed for intended pharmaceutical products and thus require the highest level of confidence in analytical results as suitable for regulated good laboratory practice (GLP), pre-clinical/clinical, pharmacokinetic and/or toxicological studies, and identification of active metabolites in safety testing (MIST). These mandate that assay precision, accuracy, selectivity, sensitivity, and stability of the analytes should be determined throughout the bioanalytical measurement process. FDA recommended evaluations should be performed 38.
* Level 2) **qualified bioanalytical** **assays** do not need to demonstrate that the measurement methods are as robust as validated assays. This tier is suitable for non- regulated studies in the drug development process, with additional assessment of tissue concentrations or other matrices during preclinical or late discovery phases, and in decision-making for context of use (COU) statements. Single method performance with a statistically appropriate number of quality controls (QC) samples (n=5) at each level and a suitable calibration range, precision and accuracy should be performed.
* Level 3) **research-grade bioanalytical assays** are suitable for mid- to late-discovery phases of drug development projects for decision-making evaluations and/or verification of additional biomarkers or metabolites for non-GLP regulated studies. They use limited characterization with calibration standards prepared using a comparator reference material such as an *in situ* (in solution) standard with the concentration estimated by radioactivity measurement, NMR or ultraviolet (UV) absorption as representative methods. The method provides semi-quantitative analyte concentrations within wider accuracy and precision limits than for the two higher tiers

39. This approach enables the partial characterisation of an analytical method that may eventually move to a qualified or validated assay. It should provide sufficient scientific rigor to ensure that it is fit-for-purpose and that there is confidence in the data. Method

evaluation should be conducted prior to sample analysis, with the precision and accuracy needed to achieve the more relaxed criteria of 20% relative standard deviation (RSD) and 30% reduction of error (RE) at the LLOQ (Lowest Limit of Quantitation).

* Level 4) **screening bioanalytical assays** apply a generic method (not specific to the analyte) to provide adequate results for the analyte of interest and are suitable for early discovery and qualitative (present/absent) analysis. Screening assays undergo limited characterization based on relative instrument analyte response where reference material is not available. The assay provides relative analyte measurements (i.e. response and not concentration) only but may still be suitable for decision-making processes. An abbreviated set of QCs with large margins of variability of 30% RSD and 40% RE is advisable. As such, screening bioanalytical assays are most similar to untargeted metabolomics assays.

 Apart from the four-tiered levels approach in the bioanalytical industry, there is a general concept of ‘full’ and ‘partial’ validation. Full validation is necessary when developing and implementing a bioanalytical method for the first time such as when analytes are added to a panel for bioanalytical quantification. In targeted metabolomics, full validation of a method by the accredited clinical laboratory is required when the result from that assay (e.g. concentration of a biomarker in terms of molarity for liquids or µg/mg for tissue) is used for making a clinical decision. Partial validation is required in the case of bioanalytical method transfers between laboratories or the method parameters such as instrument and/or software platform changes, such as changes in species within matrix (e.g. human plasma to murine plasma) or within a species (e.g. human plasma to human serum/urine). Partial validation can range from as little as one intra-assay accuracy and precision determination to nearly full validation 46 depending on the degree of change required being undertaken.

The sections above have introduced concepts and terminologies within bioanalytical validation as well as highlighting the need for the standardisation of guidelines for the validation of endogenous metabolite analysis with the aim of maximising the cross-comparability of generated data. In the next section, a flexible and practical framework to assist bioanalysts to select the appropriate tier of reliability for multiplexed metabolic biomarker assays, each with a defined use, is proposed.

**Framework for assessing the reliability of metabolomics bioanalytical methods**

 A fundamental question is how stringently regulatory bodies view these guidelines as being hard rules, or whether they could be adopted as ‘fit-for-purpose’ for targeted metabolomics assays, and used within a ‘tiered’ framework. The intended use (or application) of metabolomics drives which level of reliability assessment should be used, not the type of assay. Selecting the most appropriate tier for measuring multiple metabolic biomarkers simultaneously for targeted metabolomics assays is challenging if the intended data use is not carefully defined. Hence, the first step in selecting an appropriate tier is to define the intended use of the data and which type of assay is needed. and then the most appropriate reliability tier can be further defined. Considering that there are a range of applications for metabolomics and new advances in LC-MS techniques for multiplexed measurement of metabolites, there is a clear need to propose a new framework that describes which reliability tier is most ‘fit-for-purpose’ for different applications. Evaluation of being ‘fit-for-purpose’ involves questions such as: 1) what is the context of use for the assay (i.e. what will the data be used for); 2) should it be a quantitative, semi-quantitative or relatively quantitative assessment; and 3) what level of uncertainty can be tolerated in the assessment.

Consolidating the concept of ‘fit-for-purpose’ assists bioanalysts in decision-making on whether to qualify or validate a biomarker assay, and which parameters to choose in addition to the number of appropriate replicates 48. The end-result of a ‘fit-for-purpose’ validation of an assay using relative quantification is a resource-effective and -efficient demonstration of the bioanalytical method’s performance that is tailored to meet the objective of the application. This ultimately provides reliable study data to make important decisions. The decisions may involve further assay development and progression to a fully validated method. The following framework is proposed as a guideline for the metabolomics community to assess the reliability of targeted metabolomics assays for different types of applications (i.e. from biomarker discovery by a research laboratory, transfer of a method to a different laboratory, through to the use of biomarker within a clinical setting). The proposed framework is summarised in Table I (Tiers 1-4) to assist bioanalysts in selecting the most appropriate tier based on their purpose and assay type. Tiers 1 and 2 (targeted metabolomics) are the main focus of this manuscript, and all related parameters for safeguarding scientific rigor for robust validation and bioanalytical quantification for these two tiers (termed validation and qualification) are summarised in Table II. These tiers differ in depth, robustness of parameters, and the number of replicates performed for each parameter (See Table II).

Tier 1 - Validation

 Diagnosis of disease/toxicity phenotype using traditional targeted metabolite analysis with absolute quantification of typically one to a few (less than 10) metabolites. Tier 1 validation is required for compliance with regulatory agencies for clinical diagnostics. This requires an authentic standard (external standard) for each metabolite. The proposed procedure is in alignment with current FDA and ICH M10 bioanalytical method validation guidelines, and is applicable to quantitative analytical assays such as chromatographic, liquid chromatography-mass spectrometry (LC-MS and/or LC-MS/MS), and ligand binding assays (LBA) (see Table II).

Tier 2 - Qualification

 Diagnosis of disease/toxicity phenotype using a multiplexed targeted metabolomics assay with absolute quantification of more than 10 metabolites. This requires an authentic external standard for each metabolite. The criteria for qualifying a method are less strict than for tier 1 validation of a method (see Table II).

Tier 3 - Screening

 Screening for a disease/toxicity phenotype using a multiplexed targeted or hybrid metabolomics assay with relative or semi-quantification of a panel of hundreds of metabolites. This does not require an authentic external standard for each metabolite. The criteria to meet in a screening method are less strict than for tier 2 qualification of a method.

Tier 4 - Discovery

 Discovery of putative metabolic biomarkers using untargeted or hybrid metabolomics with relative quantification in a research laboratory. Untargeted methods have the least strict criteria. Tiers 3 and 4 are not within the scope of this manuscript as they do not require absolute quantification. Furthermore, the use of system suitability tests, intra-study QC samples, phenotyping QCs (healthy vs. disease), inter-laboratory QC samples, and dilution series of pooled QCs have been previously discussed 7, 49 and provide a dimension of semi-quantitative nature to these untargeted assays.

**Table I. Four-tiered framework for assessing the reliability of metabolomics assays**

|  |  |  |  |
| --- | --- | --- | --- |
| **Tiers of framework to evaluate reliability** | Purpose (example) | Assay type | Assay quantification |
| **1- Validation** | Diagnosis of disease/toxicity phenotype | Targeted metabolite analysis of 1 to < 10 metabolites | Absolute quantification with authentic standard(s) |
| **2- Qualification** | Diagnosis of disease/toxicity phenotype | Multiplexed targeted metabolomics analysis of > 10 metabolites | Absolute quantification with authentic standards |
| **3- Screening** | Screening for a disease/toxicity phenotype | Multiplexed targeted metabolomics analysis of panel of hundreds of metabolites | Relative or semi- quantitative; does not require an authentic standard for each metabolite |
| **4- Discovery** | Discovery of putative metabolic biomarkers | Untargeted metabolomics | Relative quantification |

**Table ІI. Biomarkers - validation *vs*. qualification**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Parameters** | **Tier 1- Validation** | **Acceptance criteria** | **Tier 2- qualification** | **Acceptance criteria** |
| **Calibrators/linearity** | * 5 independent calibration lines, minimum of 6 non-zero calibrators covering the range of incurred samples
 | * *R*2 >0.98, closer to 1 is better
* Setting LLOQ as lowest acceptable standard
 | * 3 independent calibration lines, minimum of 8 non-zero calibrators covering the range of incurred samples
 | * *R*2 >0.98, closer to 1 is better
* Setting LLOQ as lowest acceptable standard
 |
| **Assay range - lower/upper limit of quantification****(LLOQ/ULOQ)** | * Over 6 runs
 | * *R*2 >0.98
 | * Over 3 runs
 | * *R*2 >0.98
 |
| **Calibration Quality Control (QC) levels** | * Prepare LLOQ, low, medium and high QCs in 5 replicates
 | * RSD<15%, except for LLOQ (RSD<20%)
 | * Prepare LLOQ, low, medium and high QCs in 5 replicates
 | * RSD<20%, except for LLOQ (RSD<25%)
 |
| **Intra-study QC (pooled QC) levels** | * After every 6 unknown samples with the minimum number of 6 per assay
 | * At least 67% (e.g. at least four out of six) of the QCs concentration results should be within CV<15 %
 | * After every 6 unknown samples with the minimum number of 6 per assay
 | * At least 67% (e.g. at least four out of six) of the QCs concentration results should be within CV<20 %
 |
| **Precision (within- day/intra-precision)** | * Over 1 Run, 5 replicates, 4 levels (LLOQ, low, medium and high)
 | * Should not exceed 15% of the coefficient of variation (CV% or RSD%) except for the LLOQ, where it should not exceed 20% of the CV
 | * Over 1 Run, 5 replicates , 3 levels (low, medium and high)
 | * RSD<20-25%
 |
| **Precision (between- day/inter-precision)** | * Over 6 runs, 5 replicates, 4 levels (LLOQ, low, medium and high)
 | * RSD <20%, at LLOQ RSD<25%
 | * Over 3 runs, 5 replicates, 3 levels (low, medium and high)
 | * RSD<30%
 |
| **Accuracy (within- day/intra-accuracy)** | * Over 1 Run, 5 replicates, 4 levels (LLOQ, low, medium and high)
 | * Within 15% of nominal value, except for LLOQ within 20%
 | * Over 1 Run, 5 replicates, 3 levels (low, medium and high)
 | * Within 20-25% of the nominal value
 |
| **Accuracy (between- day/inter-accuracy)** | * Over 6 runs, 5 replicates, 4 levels (LLOQ, low, medium and

high) | * Within 20-25% of the nominal value
 | * Over 3 runs, 5 replicates, 3 levels (low, medium and high)
 | * Within 25-30% of the nominal value
 |
| **Selectivity/specificity/ matrix effect** | * Yes
 | * Absence of interfering compound accepted where the
 | * N/A
 | * N/A
 |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Parameters** | **Tier 1- Validation** | **Acceptance criteria** | **Tier 2- qualification** | **Acceptance criteria** |
|  |  | response is less than 20% ofLLOQ and/or less than 5% for IS |  |  |
| **Carry over** | * Yes
 | * Absence of interfering compound accepted where the response is less than 20% of LLOQ and/or less than 5% for IS
 | * Yes
 | * Absence of interfering compound accepted where the response is less than 20% of LLOQ and/or less than 5% for IS
 |
| **Parallelism** | * Yes, depending on availability of sample with high endogenous analyte from 6 individual sources of blank

matrix | * Precision between samples in a dilution series should not exceed 30%
 | * Perform 1 or 2 tests depending on availability of sample with high level of endogenous analyte
 | * The precision between samples in a dilution series should be 30%- 40%
 |
| **Dilutional Linearity/integrity** | * Yes
 | * Spike blank matrix to concentration above ULOQ and dilute it down with blank matrix (5 determinations per dilution)
* Accuracy: ± 15% of nominal concentrations
* Precision: ± 15% CV
* R2 >0.98
 | * If applicable
 | * Spike blank matrix to concentration above ULOQ and dilute it down with blank matrix (1 determinations per dilution)
* R2 >0.98
 |
| **Prozone (hook) effect** | * Yes, as applicable
 | * The calculated concentration for each dilution should be within ±20% of the nominal concentration after correction for dilution and the precision of the final concentrations across all the dilutions should not

exceed 20% | * N/A
 | * N/A
 |
| **Stability - room temperature** | * Yes
 | * The accuracy (% nominal) at each level should be ± 15%
 | * Recommended
 | * The accuracy (% nominal) at each level should be ± 25%
 |
| **Stability - 4◦C** | * Yes
 | * Same as above
 | * Recommended
 | * Same as above
 |
| **Stability - freeze/thaw** | * Yes
 | * Same as above
 | * Recommended
 | * Same as above
 |
| **Stability - long-term (-20◦C and/or -80◦C)** | * Yes
 | * Same as above
 | * N/A
 | * N/A
 |

# Bioanalytical considerations for generation of quality data in targeted and untargeted or hybrid metabolomics assays

The importance of good laboratory practice at different stages (e.g. sample collection, storage integrity) should be considered for bioanalysis. Sample, analyte and data integrity as well as basic laboratory record keeping are essential. Implementing a laboratory information management system (LIMS) is recommended. Routine calibration of laboratory instruments, pipettes and balances with well-written standard operating procedures (SOPs), as well as selection of suitable blank matrices, internal standards, system suitability test and intra-study QCs are essential. Intra-study QCs should be placed in the analytical run in such a way that the precision of the whole run is ensured by taking into account that study samples should always be bracketed by QCs 7. Phenotyping QCs (e.g. healthy *vs*. diseased) are recommended. A QC is typically produced by pooling a small aliquot of all study samples, and these are analysed throughout the analytical run. For untargeted metabolomics, a dilution series of the intra-study QC is highly recommended to help differentiate features of biological origin from LC-MS chemical background 50. Application of isotopically-labelled standards can provide a generalised measure of precision across the study. Furthermore, use of isotopically labelled internal standards helps to compensate for matrix-induced ionisation effects, thereby enhancing the accuracy of the assay when quantification/semi-quantification is applied 25. Choice of suitable surrogate matrices are recommended to improve sensitivity and selectivity of biomarkers quantification 51, 52, 53, 54. Blank matrices with the minimum level of endogenous analyte should be used wherever possible. This approach is suitable for multianalyte assays (spiked with appropriate concentration of each analyte), but matrix effects and stability should be investigated for each analyte. In the absence of blank matrices or surrogate matrices, standard addition approaches which take into account the native concentration of the targeted analyte(s) can be used for recovery and matrix effect checks; and the use of QCs or standards prepared only in solvent and/or buffer considered for accuracy and repeatability/reproducibility tests represents the approach that makes the least assumptions. Artificial blank matrices may be used. A solution of 4% fatty acid-free bovine serum albumin (BSA) in saline buffer that represents the same concentrations of salts and electrolytes in human plasma is a good example of blank matrix for human plasma (artificial surrogate matrix). Normalisation strategies to correct for differences in sample amount should be considered. For example, urinary creatinine is often used to adjust the concentration of urinary biomarkers.

All targeted assays should have a clearly defined limit of detection (LOD) and limit of quantitation (LOQ). A clearly discernible peak must be visible above clearly visible baseline noise and should be comprised of a specified number of data points (often 6 or above is used). As a general rule, LOQ of S:N (signal to noise) at least 5-10 is used by research laboratories, with an LOD of around 3:1. This approach is fully in line with guidelines from international bodies 28, 55, 56, 57, 58, 59, 60, 61, 62, 63.

For targeted assays, all peaks should be checked to ensure they reach the specified S:N ratio, as well as the required number of data points. However, for large scale metabolomics, manual checking is not feasible for all peaks, but if certain metabolites or features are judged to be discriminatory (e.g. predictive of sample type), then those should be prioritised for manual post-processing checks to ensure that the differences are real and the data is of good quality.

# Discussion

Validation is defined as the process of proving that any procedure, process, equipment, material, activity or system performs as expected within defined acceptance criteria under a given set of conditions, and that the performance characteristics of the procedure meet the requirements for the intended analytical applications 64, 65. Although implementing fail/pass criteria advised by bioanalytical method validation guidelines have provided a useful degree of standardisation and consistency between regulated laboratories, new advances in technology,

multiplexing, and metabolomics studies require tiered and/or ‘fit-for-purpose’ approaches 66

for pragmatic/practical use.

One of the challenges in targeted metabolomics is that obtaining the suitable internal standards are often difficult. On the other hand, one of the advantages of targeted biomarker assays is that the biology of the biomarker has often already been understood, so the anticipated levels, turnover rate, the intra- and inter-subject variability is known, thus enabling the analyst to develop the right assays with appropriate level of validation to generate quality data. However, for newly discovered biomarkers for which little is known, assay development should start with a focus on parallelism, selectivity and sensitivity. Then, at a later stage, the assay could be fine-tuned to the required acceptance criteria 67.

Pre-determined or fixed acceptance criteria are established and appropriate for validated assays (Tier 1); however, for qualified, research, and screening methods (Tiers 2-4), it may be appropriate to define these after the method performance experiments have been conducted to fine-tune the assay to the required acceptance criteria. Minimally, it is expected that *a priori* acceptance criteria can be relaxed for the higher tiers if such method performance still supports the intended use of the data and ultimately supports the necessary decisions that will be made 39.

Recently, regulatory bodies have begun to address the requirements needed to achieve robust and reliable data in biomarker assays applying omics data. To our knowledge, the Omics subgroup report 21 and C-Path report 68 are the only documents published by the regulatory agencies on assessment of biomarkers assays. The Omics subgroup report 21 on behalf of the EMA and Heads of Medicines Agencies (HMA) published in 2017 a checklist to introduce considerations for successful qualification of novel methodologies such as biomarker quantification, clinical outcome assessment, imaging methods and big data approaches.

This checklist entails brief recommendations for context-of-use (CoU), selection of endpoints, statistical analysis plan, demonstration of clinical utility, standard of truth/surrogate standard of truth, suitability of the analytical platform, as well as a link to ICH E16 and ICH E18 guidelines that focus on pharmacogenomics biomarkers, and sampling and management of genomic data (EMA/750178/2017 document). Furthermore, the FDA in conjunction with the Path Institute (C-Path) published a document entailing broad scientific insight to biomarker assay challenges, and a complete description of necessary approaches that can be applied to biomarkers qualification 68.

Targeted metabolomic studies often require the quantification (e.g. absolute, semi- and/or relative) of multiple analytes (e.g. multiplexing) in order to exploit putative biomarkers identified via untargeted metabolomics methods, and validate derived hypotheses. The gap between targeted and untargeted metabolomics is very narrow and often overlapping. For example, in assays for the quantification of hundreds of polar or lipophilic metabolites, authentic external standards and internal standards may not be available for all analytes. Many of these assays also satisfy the criteria for the accuracy and precision of metabolite measurements as defined by the FDA. However, they should be reported as estimated rather than absolute concentrations mainly due to lack of standard and/or internal standard availability.

LC-MS multiplexing allows for the measurement of numerous analytes in the same analytical run, thus providing significantly more information about molecular biomarker signatures than measurements of single analytes. As the number of analytes increases, favourable accuracy and precision values are often more difficult to obtain. As noted by regulatory guidelines, all quantified analytes in the same assay need to meet the same acceptance criteria. If one of the analytes fails to meet acceptance criteria, the whole analytical run fails. However, in multiplexing assays, re-analysis of the whole panel of analytes should not be necessary if most of the analytes are within the pre-defined quality specifications.

Furthermore, acceptance criteria should be widened 69, in which the variation at the LLOQ is increased from 20% to 30%-40%. One should bear in mind that increasing the number of replicates at the LLOQ will result in lower variation (RSD%). The degree of analytical variability that can be tolerated depends on biological variation. Higher variation is often expected for large biomolecules compared to metabolites. Incurred sample reanalysis (ISR) of macromolecules as recommended by the FDA is within 30% of the average of original and reanalysed values compared to 20% for small molecules 70. In the proposed framework, acceptance criteria for Tier 2 is more relaxed as size and number of replicates are lowered. However, increased calibration points for Tier 2 when the number of metabolites are increased are recommended. Furthermore, biomarkers should be simultaneously evaluated in both absolute and semi/relative quantification manners for multiplexed assays 69. For instance, identification or presence of a particular compound (e.g. qualitative evaluation) alongside quantification of related metabolites or a precursor could provide better insight into metabolic phenotyping.

Validation beyond the intended use of the data means significant re-work, loss of time and increased cost in the blind pursuit of absolute requirements. For metabolomics at its current state of development, what is required is the definition of a simple, pragmatic and easy- to-follow framework that reflects realistic and practical needs that allow for the most efficient practices. For instance, an assay that does not pass the criteria for full validation but, nevertheless, fulfils the essential requirements for linearity, accuracy, precision, LLOQ and carryover criteria may be devised. In that case, guidance should focus on minimum requirements. Specifications of merit might include: linearity with an LLOQ set as first calibrant, accuracy, precision and carryover.

Overall, the guidelines for assays developed for drugs that have been devised by regulatory authorities to ensure safety and efficacy in humans represent a ‘gold standard’ that may not be required for many types of targeted and untargeted metabolomics applications.

This is not to suggest that metabolic phenotyping methods should not be developed to the standards necessary to provide reliable and scientifically valid data but to suggest that the use of tiered approaches linked to the type of investigation is at (i.e. discovery, hypothesis validation, biomarker/panel, and/or qualification stages), should drive the level of validation performed. A number of intricate analytical factors (e.g. pre-analytical factors) defining core

assay expectations, and setting acceptable assay performance criteria, should be taken into account for assessing the reliability and quality of metabolomics assays. Our MAP/UK consensus framework provides a bench guide for the two major categories of validation and qualification of targeted metabolomics analysis that have been described in Table II.

# Conclusions

Metabolomics has the potential to lead advances in the discovery of clinically and toxicologically relevant biomarkers, yet the lack of harmonisation at different levels of processes throughout the whole metabolomics pipeline from study design, sample handling, biobanking, metabolite quantification and data analysis remain issues that need to be addressed.

Metrological tracability and future development of certified matrix reference materials similar to National Institute of Standards and Technology reference standards (NIST SRM 1950), and standard calibration mixtures should be established and harmonized within both the research and regulatory communities.

The MAP/UK consortium proposes the pragmatic development of a ‘fit-for- purpose’ 4-tiered framework for assessing the reliability of metabolomics assays via a decision-making process and adaptation of existing drug regulatory guidance. The required level of analytical rigour and/or qualification that bioanalytical methods need to achieve scientifically valid studies in metabolomics has been considered. This framework is intended to guide bioanalysts and to facilitate improved communication between the research and regulatory communities, and to enable the establishment of appropriately qualified targeted metabolomics assays to meet the needs of multiple applications of this technology in the regulatory sciences. Ultimately, this community-initiated framework can accelerate the application of metabolomics in regulatory applications and achieve acceptance via its consensus use.

# Acknowledgements

Funding – Medical Research Council (grant reference: MR/S010483/1) to the MAPUK project. Wellcome Trust for LIPID MAPS (203014/Z/16/Z) to VO’D.

# References

1. Roberts, Lee D., Amanda L. Souza, Robert E. Gerszten, and Clary B. Clish. Targeted Metabolomics. *Curr. Protoc. Mol. Biol*. **98**, no. 1 (2012): 30.2.1-30.2.24. https://doi.org/https://doi.org/10.1002/0471142727.mb3002s98.
2. Goodacre, Royston, Seetharaman Vaidyanathan, Warwick B. Dunn, George G. Harrigan, and Douglas B. Kell. Metabolomics by Numbers: Acquiring and Understanding Global Metabolite Data. *Trends Biotechnol*. **22**, no. 5 (2004/05// 2004): 245-52. https://doi.org/10.1016/j.tibtech.2004.03.007.
3. Wei, Ru, Guodong Li, and Albert B. Seymour. High-Throughput and Multiplexed Lc/Ms/Mrm Method for Targeted Metabolomics. Anal. Chem. **82**, no. 13 (2010/07// 2010): 5527-33. https://doi.org/10.1021/ac100331b.
4. Dunn, Warwick B., *et al*. Molecular Phenotyping of a Uk Population: Defining the Human Serum Metabolome. *Metabol.* : Official journal of the *Metabol. Soc.* **11** (2015): 9-26. https://doi.org/10.1007/s11306-014-0707-1.
5. Guijas, Carlos, J. Rafael Montenegro-Burke, Benedikt Warth, Mary E. Spilker, and Gary Siuzdak. Metabolomics Activity Screening for Identifying Metabolites That Modulate Phenotype. *Nat. Biotechnol*. **36**, no. 4 (2018/04/01 2018): 316-20. https://doi.org/10.1038/nbt.4101.
6. Rinschen, M. M., J. Ivanisevic, M. Giera, and G. Siuzdak. Identification of Bioactive Metabolites Using Activity Metabolomics*. Nat Rev Mol Cell Biol*. **20**, no. 6 (Jun 2019): 353-67. https://doi.org/10.1038/s41580-019-0108-4.
7. Viant, Mark R., *et al.* Use Cases, Best Practice and Reporting Standards for Metabolomics in Regulatory Toxicology. *Nat. Commun.* **10**, no. 1 (2019/07/10 2019): 3041. https://doi.org/10.1038/s41467-019-10900-y.
8. Want, Elizabeth J., Benjamin F. Cravatt, and Gary Siuzdak. The Expanding Role of Mass Spectrometry in Metabolite Profiling and Characterization. *Chem. BioChem*. **6**, no. 11 (2005): 1941-51.
9. Dunn, W. B., *et al.* Procedures for Large-Scale Metabolic Profiling of Serum and Plasma Using Gas Chromatography and Liquid Chromatography Coupled to Mass Spectrometry. *Nat Protoc.* **6**, no. 7 (Jun 30 2011): 1060-83. https://doi.org/10.1038/nprot.2011.335.
10. Gertsman, Ilya, and Bruce A. Barshop. Promises and Pitfalls of Untargeted Metabolomics. *J. Inherited Metab. Dis.* **41**, no. 3 (2018): 355-66. https://doi.org/https://doi.org/10.1007/s10545-017-0130-7.
11. Rattray, Nicholas J. W., *et al*. Metabolic Dysregulation in Vitamin e and Carnitine Shuttle Energy Mechanisms Associate with Human Frailty. *Nat. Commun*. **10**, no. 1 (2019/11/05 2019): 5027. https://doi.org/10.1038/s41467-019-12716-2.
12. Ribbenstedt, Anton, Haizea Ziarrusta, and Jonathan P. Benskin. Development, Characterization and Comparisons of Targeted and Non-Targeted Metabolomics Methods. *PLoS One.* **13**, no. 11 (2018): e0207082. https://doi.org/10.1371/journal.pone.0207082.
13. Tabassum, R., *et al.* Genetic Architecture of Human Plasma Lipidome and Its Link to Cardiovascular Disease. *Nat. Commun*. **10**, no. 1 (Sep 24 2019): 4329. https://doi.org/10.1038/s41467-019-11954-8.
14. Goutman, S. A., *et al.* Untargeted Metabolomics Yields Insight into Als Disease Mechanisms. *J Neurol Neurosurg. Psychiatry* **91**, no. 12 (Dec 2020): 1329-38. https://doi.org/10.1136/jnnp-2020-323611.
15. Palmer, Jessica A, *et al.* A Targeted Metabolomics-Based Assay Using Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes Identifies Structural and Functional Cardiotoxicity Potential. *Toxicol. Sci.* **174**, no. 2 (2020): 218-40. https://doi.org/10.1093/toxsci/kfaa015.
16. Frédérich, Michel, Bernard Pirotte, Marianne Fillet, and Pascal de Tullio. Metabolomics as a Challenging Approach for Medicinal Chemistry and Personalized Medicine. *J. Med. Chem.* **59**, no. 19 (2016/10/13 2016): 8649-66.

https://doi.org/10.1021/acs.jmedchem.5b01335.

1. Beger, R. D., *et al.* Metabolomics Enables Precision Medicine: A White Paper, Community Perspective. *Metabol.* **12**, no. 10 (2016): 149. https://doi.org/10.1007/s11306-016-1094-6.
2. Mandal, Rupasri, Danuta Chamot, and David S. Wishart. The Role of the Human Metabolome Database in Inborn Errors of Metabolism. *J. Inherited Metab. Dis*. **41**, no. 3 (2018/05/01 2018): 329-36. https://doi.org/10.1007/s10545-018-0137-8.
3. Burla, B., *et al.* Ms-Based Lipidomics of Human Blood Plasma: A Community-Initiated Position Paper to Develop Accepted Guidelines. *J Lipid Res.* **59**, no. 10 (Oct 2018): 2001-

17. https://doi.org/10.1194/jlr.S087163.

1. Thompson, J. W., *et al.* International Ring Trial of a High Resolution Targeted Metabolomics and Lipidomics Platform for Serum and Plasma Analysis. *Anal. Chem.* **91**, no. 22 (Nov 19 2019): 14407-16. https://doi.org/10.1021/acs.analchem.9b02908.
2. Renate König, Alison Cave, Mark Goldammer, and Didier Meulendijks. Bioanalytical Omics Subgroup Report. Heads of Medicines Agencies (HMA) and European Medicine Agency (EMA) (n.d.). [https://w](http://www.ema.europa.eu/en/documents/report/bioanalytical-)ww.ema.e[uropa.eu/en/documents/report/bioanalytical-](http://www.ema.europa.eu/en/documents/report/bioanalytical-) omics-subgroup-report\_en.pdf.
3. Harrill, J. A., *et al.* Progress towards an OECD Reporting Framework for Transcriptomics and Metabolomics in Regulatory Toxicology. *Regul Toxicol Pharmacol.* **125** (Oct 2021): 105020. https://doi.org/10.1016/j.yrtph.2021.105020.
4. Dunn, W. B., D. I. Broadhurst, H. J. Atherton, R. Goodacre, and J. L. Griffin. Systems Level Studies of Mammalian Metabolomes: The Roles of Mass Spectrometry and Nuclear Magnetic Resonance Spectroscopy. *Chem Soc Rev*. **40**, no. 1 (Jan 2011): 387-426. https://doi.org/10.1039/b906712b.
5. Dunn, Warwick B., *et al.* Quality Assurance and Quality Control Processes: Summary of a Metabolomics Community Questionnaire. *Metabolom.* **13**, no. 5 (2017/03/06 2017): 50. https://doi.org/10.1007/s11306-017-1188-9.
6. Broadhurst, David, *et al.* Guidelines and Considerations for the Use of System Suitability and Quality Control Samples in Mass Spectrometry Assays Applied in Untargeted Clinical Metabolomic Studies. *Metabolom.* : Official J of the *Metabolom. Soci.* **14**, no. 6 (2018 2018): 72. https://doi.org/10.1007/s11306-018-1367-3.
7. Hyötyläinen, Tuulia, Linda Ahonen, Päivi Pöhö, and Matej Orešič. Lipidomics in Biomedical Research-Practical Considerations. *Biochimica et Biophysica Acta*. (BBA) – *Mol. and Cell Biol of Lipids* **1862**, no. 8 (2017/08/01/ 2017): 800-03. https://doi.org/https://doi.org/10.1016/j.bbalip.2017.04.002.
8. Beger, R. D., *et al.* Towards Quality Assurance and Quality Control in Untargeted Metabolomics Studies. *Metabolom*. **15**, no. 1 (Jan 3 2019): 4. https://doi.org/10.1007/s11306-018-1460-7.
9. U.S. Department of Health and Human, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), and Center for Veterinary Medicine (CVM).

Bioanalytical Method Validation, Guidance for Industry. (2018). [https://w](http://www.fda.gov/media/70858/download)ww.fda.g[ov/media/70858/download.](http://www.fda.gov/media/70858/download)

1. European Medicine. Guideline on Bioanalytical Method Validation. Committee for Medicinal Products for Human Use (CHMP), (2011). [https://w](http://www.ema.europa.eu/en/documents/scientific-guideline/guideline-bioanalytical-)ww.ema.e[uropa.eu/en/documents/scientific-guideline/guideline-bioanalytical-](http://www.ema.europa.eu/en/documents/scientific-guideline/guideline-bioanalytical-) method-validation\_en.pdf.
2. International Commitee of Harmonisation/European Medicine. Ich Guideline M10 on Bioanalytical Method Validation. (2019). [https://w](http://www.ema.europa.eu/en/documents/scientific-guideline/draft-ich-guideline-)ww.ema.e[uropa.eu/en/documents/scientific-guideline/draft-ich-guideline-](http://www.ema.europa.eu/en/documents/scientific-guideline/draft-ich-guideline-) m10-bioanalytical-method-validation-step-2b\_en.pdf.
3. Ministry of Health and Welfare, Japan. Draft Guideline on Bioanalytical Method Validation in Pharmaceutical Development (2013). [https://w](http://www.nihs.go.jp/drug/BMV/BMV_draft_130415_E.pdf)ww.nihs.[go.jp/drug/BMV/BMV\_draft\_130415\_E.pdf.](http://www.nihs.go.jp/drug/BMV/BMV_draft_130415_E.pdf)
4. China Food and Drug Administration (CFDA), Good Manufacturing Practice for Drugs (2010 Revision), MOH Decree No. 79, [https://w](http://www.gmpsop.com/RegulatoryReference/CFDA/China_SFDA_Good_Manufacturi)ww.gm[psop.](http://www.gmpsop.com/RegulatoryReference/CFDA/China_SFDA_Good_Manufacturi)com[/RegulatoryReference/CFDA/China\_SFDA\_Good\_Manufacturi](http://www.gmpsop.com/RegulatoryReference/CFDA/China_SFDA_Good_Manufacturi) ng\_Practice\_for\_Drugs.pdf. Accessed March 2022.
5. Austrilian government, Therapeutic Goods Administration, Finished product (medicine) analytical procedure validations for Complementary Medicines, March 2006, [https://w](http://www.tga.gov.au/sites/default/files/cm-analytical-procedure-finished.pdf)ww.tga.g[ov.au/sites/default/files/cm-analytical-procedure-finished.pdf.](http://www.tga.gov.au/sites/default/files/cm-analytical-procedure-finished.pdf)

Accessed March 2022.

1. ANVISA Guide for validation of analytical and bioanalytical methods. Resolution RE no.

899, 23 May 2003 Brazilian Sanitary Surveillance Agency, BrazilGoogle Scholar.

1. Anvisa. Guide for Validation of Analytical and Bioanalytical Methods. . ANVISA Brazil (2012).
2. Huynh-Ba, Kim, and Alexandra Beumer Sassi. Anvisa: An Introduction to a New Regulatory Agency with Many Challenges. *AAPS Open* **4**, no. 1 (2018/12/12 2018): 9. https://doi.org/10.1186/s41120-018-0029-x.
3. Viswanathan, C. T., *et al.* Quantitative Bioanalytical Methods Validation and Implementation: Best Practices for Chromatographic and Ligand Binding Assays. *Pharm Res.* **24**, no. 10 (Oct 2007): 1962-73. https://doi.org/10.1007/s11095-007-9291-7.
4. Timmerman, P., *et al.* Best Practices in a Tiered Approach to Metabolite Quantification: Views and Recommendations of the European Bioanalysis Forum. *Bioanal.* **2**, no. 7 (Jul 2010): 1185-94. https://doi.org/10.4155/bio.10.90.
5. Lowes, S., *et al.* Tiered Approaches to Chromatographic Bioanalytical Method Performance Evaluation: Recommendation for Best Practices and Harmonization from the Global Bioanalysis Consortium Harmonization Team. *The AAPS Journal* **17** (2015): 17- 23.
6. Nakamura, T. 7th Japan Bioanalysis Forum Symposium: Regulated Bioanalysis, to a New Stage. *Bioanal.* **8**, no. 20 (Oct 2016): 2097-102. https://doi.org/10.4155/bio-2016-4995.
7. Kadian, N., *et al.* Comparative Assessment of Bioanalytical Method Validation Guidelines for Pharmaceutical Industry. *J Pharm Biomed Anal.* **126** (Jul 15 2016): 83-97. https://doi.org/10.1016/j.jpba.2016.03.052.
8. Booth, B., *et al.* Workshop Report: Crystal City V--Quantitative Bioanalytical Method Validation and Implementation: The 2013 Revised Fda Guidance. *The AAPS journal* **17**, no. 2 (2015/03// 2015): 277-88. https://doi.org/10.1208/s12248-014-9696-2.
9. GBC, Global Bioanalysis Consortium on Harmonisation of bioanalytical guidance, accessed Sept 2020, https://sites.google.com/site/globalbioanalysisconsortium/
10. Timmerman, P., *et al.* Tiered Approach into Practice: Scientific Validation for Chromatography-Based Assays in Early Development - a Recommendation from the European Bioanalysis Forum. *Bioanal.* **7**, no. 18 (Sep 2015): 2387-98. https://doi.org/10.4155/bio.15.168.
11. Lavezzari, G., and A. W. Womack. Industry Perspectives on Biomarker Qualification*. Clin Pharmacol Ther*. **99**, no. 2 (Feb 2016): 208-13. https://doi.org/10.1002/cpt.264.
12. Shah, Vinod P., *et al.* Bioanalytical Method Validatiož a Revisit with a Decade of Progress. *Pharm. Res.* **17** (2004): 1551-57.
13. Theodorsson, Elvar. Validation and Verification of Measurement Methods in Clinical Chemistry. *Bioanal.* **4**, no. 3 (2012): 305-20. https://doi.org/10.4155/bio.11.311. [https://w](http://www.future-science.com/doi/abs/10.4155/bio.11.311)ww.f[uture](http://www.future-science.com/doi/abs/10.4155/bio.11.311)-sci[ence.com/doi/abs/10.4155/bio.11.311.](http://www.future-science.com/doi/abs/10.4155/bio.11.311)
14. Safavi A., Explotatory Biomarker Testing-to Qualify or Validate the Assay? Bioagilityx Insight, 2019, accessed Feb. 2021, 2021, [https://w](http://www.bioagilytix.com/blog/2019/08/28/webinar-sneak-peek-exploratory-)ww.bioag[ilytix.com/blog/2019/08/28/webinar-sneak-peek-exploratory-](http://www.bioagilytix.com/blog/2019/08/28/webinar-sneak-peek-exploratory-) biomarker-testing-to-qualify-or-validate-the-assay/.
15. Lewis M, *et al.* An Open Platform for Large Scale LC-MS-Based Metabolomics .

*ChemRxiv.* Cambridge: Cambridge Open Engage; 2022; This content is a preprint and has not been peer-reviewed.

1. Saigusa D, *et al.* (2016) Establishment of Protocols for Global Metabolomics by LC-MS for Biomarker Discovery. *PLoS ONE* **11**(8): e0160555. https://doi.org/10.1371/journal.pone.0160555.
2. Van de Merbel, Nico C. Quantitative Determination of Endogenous Compounds in Biological Samples Using Chromatographic Techniques. *TrAC Trends Anal. Chem.* **27**, no. 10 (2008/11/01/ 2008): 924-33.

https://doi.org/https://doi.org/10.1016/j.trac.2008.09.002. [https://w](http://www.sciencedirect.com/science/article/pii/S016599360800191X)ww.scie[ncedirect.com/sci](http://www.sciencedirect.com/science/article/pii/S016599360800191X)e[nce/article/pii/S016599360800191X.](http://www.sciencedirect.com/science/article/pii/S016599360800191X)

1. Thakare, R., Y. S. Chhonker, N. Gautam, J. A. Alamoudi, and Y. Alnouti. Quantitative Analysis of Endogenous Compounds. *J Pharm Biomed Anal.* **128** (Sep 5 2016): 426-37. https://doi.org/10.1016/j.jpba.2016.06.017.
2. Tsikas, Dimitrios. "Bioanalytical Method Validation of Endogenous Substances According to Guidelines by the Fda and Other Organizations: Basic Need to Specify Concentration Ranges." Journal of Chromatography B 1093-1094 (2018/09/01/ 2018): 80-81. https://doi.org/https://doi.org/10.1016/j.jchromb.2018.07.005. [https://w](http://www.sciencedirect.com/science/article/pii/S1570023218308419)ww.scie[ncedirect.com/sci](http://www.sciencedirect.com/science/article/pii/S1570023218308419)e[nce/article/pii/S1570023218308419.](http://www.sciencedirect.com/science/article/pii/S1570023218308419)
3. Wakamatsu, A., *et al*. Proposed Selection Strategy of Surrogate Matrix to Quantify Endogenous Substances by Japan Bioanalysis Forum Dg2015-15*. Bioanal*. **10**, no. 17 (2018/09/01 2018): 1349-60. https://doi.org/10.4155/bio-2018-0105.
4. Research, C. f. D. E. a., and C. f. B. E. a. Research. 2015. https://[www.fda.gov/regulatory-](http://www.fda.gov/regulatory-) information/search-fda-guidance-documents/analytical-procedures-and-methods- validation-drugs-and-biologics. https:[//w](http://www.fda.gov/regulatory-information/search-fda-)ww[.fda.gov/regulatory-information/search-fda-](http://www.fda.gov/regulatory-information/search-fda-) guidance-documents/analytical-procedures-and-methods-validation-drugs-and- biologics.
5. Araujo, P. 2009. Key aspects of analytical method validation and linearity evaluation*. J Chromatogr B Analyt Technol Biomed Life Sci.* **877**: 2224-2234.
6. Commission, E. 2002. 2002/657/EC: Commission Decision of 12 August 2002 implementing Council Directive 96/23/EC concerning the performance of analytical methods and the interpretation of results (Text with EEA relevance) (notified under

document number C (2002) 3044) https://op.europa.eu/en/publication-detail/-

/publication/ed928116-a955-4a84-b10a-cf7a82bad858/language-en.

1. Desimoni, E., Brunetti, B. 2015. Signal to noise ratio; Limit of detection; Standard error of the regression; Chromatographic/Voltammetric/Spectroscopic signals. *Pharm. Anal.*

*ACTA*. **6** (04).

1. Heyden, Y. V. B., R. (2009) The limit of detection, LCGC Europe, [https://w](http://www.researchgate.net/profile/Stefano_Polesello/post/How_to_calculate_LOD_)ww.resea[rchgate.net/profile/Stefano\_Polesello/post/How\_to\_calculate\_LOD\_](http://www.researchgate.net/profile/Stefano_Polesello/post/How_to_calculate_LOD_) and\_LOQ\_of\_analyte\_by\_hplc/attachment/59d6356379197b8077992f7e/AS:384058174 525440@1468578012222/download/The+Limit+of+Detection-LCGC.doc.
2. Wenzl, T., Haedrich, J, Schaechtele, A, Robouch, P, Stroka, J. 2016. Guidance Document on the Estimation of LOD and LOQ for Measurements in the Field of Contaminants in Feed and Food. EUR 28099; Publications Office of the European Union: Luxembourg, https://publications.jrc.ec.europa.eu/repository/bitstream/JRC102946/eur%2028099%2 0en\_lod%20loq%20guidance%20document.pdf.
3. [http://www.pharmacopeia.cn/v29240/usp29nf24s0\_c1225.html.](http://www.pharmacopeia.cn/v29240/usp29nf24s0_c1225.html)
4. [https://w](http://www.ema.europa.eu/en/ich-q2-r1-validation-analytical-procedures-text-)ww.ema.e[uropa.eu/en/ich-q2-r1-validation-analytical-procedures-text-](http://www.ema.europa.eu/en/ich-q2-r1-validation-analytical-procedures-text-) methodology.
5. [https://w](http://www.who.int/medicines/areas/quality_safety/quality_assurance/28092018Guid)ww.who.i[nt/medicines/areas/quality\_safety/quality\_assurance/28092018Guid](http://www.who.int/medicines/areas/quality_safety/quality_assurance/28092018Guid) eline\_Validation\_AnalyticalMethodValidation-Appendix4\_QAS16-671.pdf.
6. Watson, D.G. *Pharmaceutical Analysis*. Second Edition. Oxford: Elsevier churchill livingstone, 2005.
7. Bliesner, D.M. *Validating Chromatographic Methods: A Practical Guide*, Hoboken: Wiely Interscience, 2006.
8. Lee, J. W., *et al.* Fit-for-Purpose Method Development and Validation for Successful Biomarker Measurement. *Pharm Res.* **23**, no. 2 (Feb 2006): 312-28. https://doi.org/10.1007/s11095-005-9045-3.
9. Goodman, J., *et al.* Update to the European Bioanalysis Forum Recommendation on Biomarkers Assays; Bringing Context of Use into Practice. *Bioanal.* **12**, no. 20 (Oct 2020): 1427-37. https://doi.org/10.4155/bio-2020-0243.
10. EMA. Essential Considerations for Successful Qualification of Novel Methodologies.

European Medicine Agency (2017). [https://w](http://www.ema.europa.eu/en/documents/other/essential-considerations-successful-)ww.ema.e[uropa.eu/en/documents/other/essential-considerations-successful-](http://www.ema.europa.eu/en/documents/other/essential-considerations-successful-) qualification-novel-methodologies\_en.pdf.

1. Biomarker assay collaborative evidentiary consideration writing group. Points to Consider Document: Scientific and Regulatory Considerations for the Analytical Validation of Assays Used in the Qualification of Biomarkers in Biological Matrices. Critical Path Institute (2019). https://c-path.org/wp- content/uploads/2019/06/evidconsid-whitepaper-analyticalsection2019.pdf.
2. Christians, Uwe, *et al.* Mass Spectrometry-Based Multiplexing for the Analysis of Biomarkers in Drug Development and Clinical Diagnostics — How Much Is Too Much? *Microchem. J.* **105** (2012/11/01/ 2012): 32-38.
3. Thway, Theingi M., et al. Assessment of Incurred Sample Reanalysis for Macromolecules to Evaluate Bioanalytical Method Robustness: Effects from Imprecision. The AAPS J. 13, no. 2 (2011): 291-98. https://doi.org/10.1208/s12248-011-9271-z. https://pubmed.ncbi.nlm.nih.gov/21461973.